| Title |
Emerging Targets and Novel Approaches to Ebola Virus Prophylaxis and Treatment
|
|---|---|
| Published in |
BioDrugs, June 2013
|
| DOI | 10.1007/s40259-013-0046-1 |
| Pubmed ID | |
| Authors |
Jin Huk Choi, Maria A. Croyle |
| Abstract |
Ebola is a highly virulent pathogen causing severe hemorrhagic fever with a high case fatality rate in humans and non-human primates (NHPs). Although safe and effective vaccines or other medicinal agents to block Ebola infection are currently unavailable, a significant effort has been put forth to identify several promising candidates for the treatment and prevention of Ebola hemorrhagic fever. Among these, recombinant adenovirus-based vectors have been identified as potent vaccine candidates, with some affording both pre- and post-exposure protection from the virus. Recently, Investigational New Drug (IND) applications have been approved by the US Food and Drug Administration (FDA) and phase I clinical trials have been initiated for two small-molecule therapeutics: anti-sense phosphorodiamidate morpholino oligomers (PMOs: AVI-6002, AVI-6003) and lipid nanoparticle/small interfering RNA (LNP/siRNA: TKM-Ebola). These potential alternatives to vector-based vaccines require multiple doses to achieve therapeutic efficacy, which is not ideal with regard to patient compliance and outbreak scenarios. These concerns have fueled a quest for even better vaccination and treatment strategies. Here, we summarize recent advances in vaccines or post-exposure therapeutics for prevention of Ebola hemorrhagic fever. The utility of novel pharmaceutical approaches to refine and overcome barriers associated with the most promising therapeutic platforms are also discussed. |
X Demographics
The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 17% |
| Australia | 1 | 17% |
| Unknown | 4 | 67% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 3 | 50% |
| Members of the public | 3 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 196 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Mexico | 2 | 1% |
| India | 2 | 1% |
| United States | 2 | 1% |
| Brazil | 1 | <1% |
| United Kingdom | 1 | <1% |
| Russia | 1 | <1% |
| Kenya | 1 | <1% |
| Japan | 1 | <1% |
| Spain | 1 | <1% |
| Other | 0 | 0% |
| Unknown | 184 | 94% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 44 | 22% |
| Researcher | 31 | 16% |
| Student > Master | 28 | 14% |
| Student > Ph. D. Student | 20 | 10% |
| Other | 12 | 6% |
| Other | 30 | 15% |
| Unknown | 31 | 16% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 44 | 22% |
| Agricultural and Biological Sciences | 44 | 22% |
| Biochemistry, Genetics and Molecular Biology | 16 | 8% |
| Immunology and Microbiology | 11 | 6% |
| Nursing and Health Professions | 8 | 4% |
| Other | 35 | 18% |
| Unknown | 38 | 19% |
Attention Score in Context
This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 March 2020.
All research outputs
#3,094,006
of 23,700,294 outputs
Outputs from BioDrugs
#84
of 683 outputs
Outputs of similar age
#26,826
of 197,102 outputs
Outputs of similar age from BioDrugs
#4
of 10 outputs
Altmetric has tracked 23,700,294 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 683 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.6. This one has done well, scoring higher than 86% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 197,102 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 85% of its contemporaries.
We're also able to compare this research output to 10 others from the same source and published within six weeks on either side of this one. This one has scored higher than 6 of them.